| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MDXG Stock Overview
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
MiMedx Group Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.88 |
| 52 Week High | US$15.99 |
| 52 Week Low | US$3.27 |
| Beta | 1.92 |
| 1 Month Change | -11.01% |
| 3 Month Change | -17.27% |
| 1 Year Change | -58.94% |
| 3 Year Change | 16.87% |
| 5 Year Change | -72.79% |
| Change since IPO | -23.92% |
Recent News & Updates
Shareholder Returns
| MDXG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.8% | 0.1% | -2.5% |
| 1Y | -58.9% | -21.7% | -10.4% |
Return vs Industry: MDXG underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: MDXG underperformed the US Market which returned -10.4% over the past year.
Price Volatility
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MDXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MDXG's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 811 | Tim Wright | https://www.mimedx.com |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
MiMedx Group Fundamentals Summary
| MDXG fundamental statistics | |
|---|---|
| Market Cap | US$436.47m |
| Earnings (TTM) | -US$18.65m |
| Revenue (TTM) | US$257.54m |
1.7x
P/S Ratio-23.4x
P/E RatioIs MDXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXG income statement (TTM) | |
|---|---|
| Revenue | US$257.54m |
| Cost of Revenue | US$43.58m |
| Gross Profit | US$213.96m |
| Other Expenses | US$232.61m |
| Earnings | -US$18.65m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 83.08% |
| Net Profit Margin | -7.24% |
| Debt/Equity Ratio | 56.7% |
How did MDXG perform over the long term?
See historical performance and comparisonValuation
Is MiMedx Group undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
In this section, we usually try to help investors determine whether MiMedx Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MiMedx Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Future Growth
How is MiMedx Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
68.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDXG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: MDXG is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MDXG's is expected to become profitable in the next 3 years.
Revenue vs Market: MDXG's revenue (13.4% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: MDXG's revenue (13.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDXG's Return on Equity is forecast to be high in 3 years time
Past Performance
How has MiMedx Group performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-48.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDXG is currently unprofitable.
Growing Profit Margin: MDXG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDXG is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.
Accelerating Growth: Unable to compare MDXG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDXG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MDXG has a negative Return on Equity (-14.57%), as it is currently unprofitable.
Financial Health
How is MiMedx Group's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MDXG's short term assets ($135.9M) exceed its short term liabilities ($36.6M).
Long Term Liabilities: MDXG's short term assets ($135.9M) exceed its long term liabilities ($52.8M).
Debt to Equity History and Analysis
Debt Level: MDXG has more cash than its total debt.
Reducing Debt: MDXG's debt to equity ratio has increased from 0% to 56.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDXG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MDXG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 40.8% each year
Dividend
What is MiMedx Group current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDXG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDXG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDXG has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Tim Wright (63 yo)
3yrs
Tenure
US$4,729,903
Compensation
Mr. Timothy R. Wright, also known as Tim, MBA, has been a Director of MiMedx Group, Inc. since June 17, 2019. He has been the Chief Executive Officer at MiMedx Group, Inc. since joining on May 13, 2019. Mr...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD4.73M) is above average for companies of similar size in the US market ($USD2.64M).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: MDXG's management team is considered experienced (2.2 years average tenure).
Board Members
Experienced Board: MDXG's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MDXG insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Top Shareholders
Company Information
MiMedx Group, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: MiMedx Group, Inc.
- Ticker: MDXG
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$436.470m
- Shares outstanding: 112.49m
- Website: https://www.mimedx.com
Number of Employees
Location
- MiMedx Group, Inc.
- 1775 West Oak Commons Court, NE
- Marietta
- Georgia
- 30062
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/14 00:00 |
| End of Day Share Price | 2022/05/13 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.